Condition: Hodgkin Lymphoma · Refractory Hodgkin Lymphoma · Relapsed Hodgkin's Disease, Adult · Sponsor: Hospital Regional de Alta Especialidad del Bajio
The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT. What is the progression-free survival and rate of metabolic responses complete in patients with high-risk R/R HL with the treatment strategy: BV+ PD-1 blockade consolidation with Auto-HSCT and maintenance with BV + PD-blockade 1?
This description comes directly from the study's public registry record.
Lauro Fabián Amador, PhD · 4772697907 · lafab2013@gmail.com
JUAN Ojeda Tovar, MD · (477) 267 2000 · juan_ojeda82@hotmail.com
Always discuss trial participation with your own doctor first.
| Hospital Regional Alta Especialidad Bajio | León, Guanajuato, Mexico | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05595447